SFEBES2009 Poster Presentations Reproduction (23 abstracts)
Twice-weekly administration of kisspeptin leads to long-term stimulation of reproductive hormone release in infertile women with hypothalamic amenorrhoea
Channa N Jayasena 1 , Gurjinder M K Nijher 1, , Ali Abbara 1 , Kevin G Murphy 1 , Adrian Lim 2 , Daksha Patel 2 , Amrish Mehta 2 , Catriona Todd 2 , Radha Ramachandran 1, , Mandy Donaldson 3 , Geoffrey Trew 4 , Mohammad A Ghatei 1 , Stephen R Bloom 1 & Waljit S Dhillo 1
1Department of Investigative Medicine, Imperial College London, Hammersmith Hospital, London, UK; 2Imaging Department, Imperial College Healthcare NHS Trust, London, UK; 3Department of Clinical Biochemistry, Imperial College Healthcare NHS Trust, London, UK; 4Assisted Conception Unit, Department of Reproductive Medicine and Surgery, Imperial College Healthcare NHS Trust, London, UK.
Background: Hypothalamic amenorrhoea (HA) accounts for over 30% of cases of amenorrhoea in women of reproductive age. Current treatments have limited success rates and side effects. We have recently shown that a single injection of the novel hormone kisspeptin potently stimulates reproductive hormone release in women with HA. However, twice-daily kisspeptin administration to women with HA, results in tachyphylaxis due to desensitisation of the kisspeptin receptor. This suggests that less frequent administration of kisspeptin may lead to sustained reproductive hormone release in women with HA, which would have therapeutic implications.
Aim: To determine if long-term twice-weekly kisspeptin administration chronically stimulates reproductive hormone release in women with HA.
Methods: We performed an ethically approved prospective, randomised, single-blinded, parallel design study. Patients with HA received twice-weekly s.c. injection of either kisspeptin (6.4 nmol/kg) or saline (n=5/group) for 56 days. On days 0, 14, 28, 42 and 56, blood was sampled at regular intervals for 4 h post-injection for measurement of plasma LH and FSH.
Results: Women were more responsive to kisspeptin injection on day 0 than day 14 (mean maximal LH increase in IU/l: day 0, 21.5±10.7; day 14, 10.0±4.3; P<0.001). However there was no further significant drop in responsiveness to kisspeptin beyond day 14 (mean maximal LH increase in IU/l: day 28, 9.0±4.1; day 42, 8.9±3.5; day 56, 7.9±4.5; P>0.05 versus response on day 14). On the last (56th) day, women with HA were still 16 times more response to kisspeptin than saline. No adverse effects following kisspeptin administration were observed during the study.
Conclusion: In this first long-term study of kisspeptin administration to women with HA, we have demonstrated that twice-weekly kisspeptin administration stimulates reproductive hormone release in a sustained manner. Thus kisspeptin may be a future novel therapy for reproductive disorders.
Volume 21
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more